AbbVie posts $8.3B in Q4 earnings, misses analysts' predictions — 5 insights

AbbVie announced its fourth quarter and full year financial results, posting $8.3 billion in quarterly net revenues, up 7.3 percent year over year.

What you should know:

1. Despite the revenue gains, AbbVie missed analysts' quarterly estimates, TheStreet reports. AbbVie reported earnings of $1.90 per share, however analysts expected earnings of $1.93 per share and revenues of $8.37 billion.

2. AbbVie posted full year revenues of $32.75 billion, up from 2017's $28.22 billion in revenues.

3. AbbVie increased Humira's U.S. sales 9.1 percent year over year. Worldwide, Humira's sales decreased 14.8 percent because of emerging biosimilars.

4. AbbVie announced its full-year 2019 guidance. The company expects to post diluted earnings of $8.65 to $8.75 per share.

5. AbbVie Chairman and CEO Richard Gonzalez said, "We're entering an important new phase for AbbVie. The continued momentum of our business, combined with the launch and ramp of several new products, will allow us to drive strong earnings growth once again in 2019 and position us for growth over the longer term."

More articles on gastroenterology:
Spencer Hospital reopens surgery center after fire — 3 insights
10 ASCs focused on GI & endoscopy
Buying refurbished medical equipment? Ask these 5 Qs first

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months